[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
2. Edwards H, Xie C, LaFiura KM, Dombkowski AA, Buck SA, Boerner JL, Taub JW, Matherly LH, Ge Y: RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood; 2009 Sep 24;114(13):2744-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia.
  • Translocations or down-regulation of RUNX1 have been linked to favorable clinical outcomes in acute leukemias, suggesting that RUNX1 may also play critical roles in chemotherapy responses in acute leukemias; however, the molecular mechanisms remain unclear.
  • The median level of RUNX1b transcripts in Down syndrome (DS) children with acute megakaryocytic leukemia (AMkL) were 4.4-fold (P < .001) lower than that in non-DS AMkL cases.
  • Our results suggest that RUNX1 may play a critical role in chemotherapy response in AMkL by regulating the PI3-kinase/Akt pathway.
  • Thus, the treatment of AMkL may be improved by integrating PI3-kinase or Akt inhibitors into the chemotherapy of this disease.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Dec 1;94(11):3707-16 [10572083.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3679-87 [15226186.001]
  • [Cites] Leukemia. 2000 May;14(5):786-91 [10803507.001]
  • [Cites] Leukemia. 2000 May;14(5):943-4 [10803530.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2405-11 [11001891.001]
  • [Cites] Cancer Invest. 2000;18(8):768-80 [11107447.001]
  • [Cites] J Biol Chem. 2001 Mar 23;276(12):8713-9 [11106643.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3727-32 [11389009.001]
  • [Cites] Blood. 2002 Jan 1;99(1):245-51 [11756178.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1364-72 [11830488.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1622-6 [12200673.001]
  • [Cites] JAMA. 2005 Jan 12;293(2):203-11 [15644547.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):226-31 [15687366.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1063-6 [15840695.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1495-6 [15920489.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1355-60 [15920490.001]
  • [Cites] Blood. 2006 Feb 1;107(3):880-4 [16123215.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1570-81 [16249385.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1806-9 [16291592.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3339-44 [16492768.001]
  • [Cites] Bioinformatics. 2006 May 1;22(9):1111-21 [16522673.001]
  • [Cites] Blood. 2006 May 1;107(9):3463-8 [16384925.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4508-13 [16493009.001]
  • [Cites] Leukemia. 2006 Jun;20(6):911-28 [16642045.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3904-11 [16921041.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):621-81 [16968952.001]
  • [Cites] Cancer. 2007 Jan 1;109(1):157-63 [17133407.001]
  • [Cites] Oncologist. 2007 Mar;12(3):341-55 [17405900.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Sep;63(3):215-30 [17658267.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7 Suppl):1066-9 [17943965.001]
  • [Cites] Leukemia. 2008 Mar;22(3):521-9 [18094719.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Oncogene. 2008 Aug 21;27(36):4933-42 [18469864.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4220-6 [18755984.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1551-7 [12393509.001]
  • [Cites] Am J Hematol. 2003 Jun;73(2):71-80 [12749007.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3415-22 [12885836.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2249-50 [14523475.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4255-62 [15156181.001]
  • [Cites] Blood. 1992 Nov 1;80(9):2210-4 [1384797.001]
  • [Cites] Leuk Res. 1994 Mar;18(3):163-71 [8139285.001]
  • [Cites] Science. 1995 Jun 23;268(5218):1766-9 [7792603.001]
  • [Cites] Cell. 1996 Jan 26;84(2):321-30 [8565077.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3444-9 [8622955.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1428-34 [8618581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12359-63 [8901586.001]
  • [Cites] Cell. 1996 Nov 15;87(4):697-708 [8929538.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14059-64 [8943060.001]
  • [Cites] Blood. 1998 Jan 15;91(2):608-15 [9427716.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):166-75 [10508512.001]
  • [Cites] Gene. 2000 Mar 21;245(2):223-35 [10717473.001]
  • (PMID = 19638627.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES006639; United States / NCI NIH HHS / CA / R01 CA120772; United States / NCI NIH HHS / CA / CA120772; United States / NIEHS NIH HHS / ES / P30 ES06639
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RNA, Small Interfering; 0 / RUNX1 protein, human; 04079A1RDZ / Cytarabine; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / Class I Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CD protein, human; EC 2.7.11.1 / Oncogene Protein v-akt
  • [Other-IDs] NLM/ PMC2756129
  •  go-up   go-down


3. Ge Y, Jensen TL, Matherly LH, Taub JW: Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. Blood; 2003 Feb 15;101(4):1551-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines.
  • In this study, we examined the transcriptional regulation of the CBS gene in the DS megakaryocytic leukemia (AMkL) cell line, CMK, characterized by significantly higher CBS transcripts compared with the non-DS AMkL cell line, CMS.
  • Decreased binding of Sp1/Sp3 in CMK nuclear extracts following treatment with calf alkaline phosphatase suggested a role for phosphorylation of Sp1/Sp3 in regulating CBS promoter activity and in the differential CBS expression between CMK and CMS cells.
  • The results of this study with clinically relevant cell line models suggest potential mechanisms for disparate patterns of CBS gene expression in DS and non-DS myeloblasts and may, in part, explain the greater sensitivity to chemotherapy shown by patients with DS AML.
  • [MeSH-minor] Cytarabine / metabolism. Cytarabine / pharmacology. DNA / metabolism. DNA-Binding Proteins / metabolism. Humans. Luciferases / genetics. Mutagenesis, Site-Directed. Phosphorylation. Promoter Regions, Genetic. Sp1 Transcription Factor / metabolism. Sp3 Transcription Factor. Transcription Factors / metabolism. Transcription, Genetic. Transfection. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12393509.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA92308
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / SP3 protein, human; 0 / Sp1 Transcription Factor; 0 / Transcription Factors; 04079A1RDZ / Cytarabine; 148710-94-5 / Sp3 Transcription Factor; 9007-49-2 / DNA; EC 1.13.12.- / Luciferases; EC 4.2.1.22 / Cystathionine beta-Synthase
  •  go-up   go-down


Advertisement
4. Léger DY, Battu S, Liagre B, Beneytout JL, Cardot PJ: Megakaryocyte cell sorting from diosgenin-differentiated human erythroleukemia cells by sedimentation field-flow fractionation. Anal Biochem; 2006 Aug 1;355(1):19-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anticancer differentiation therapy could be one strategy to stop cancer cell proliferation.
  • Human erythroleukemia (HEL) cell line, incubated with 10 microM diosgenin, underwent megakaryocytic differentiation.
  • Thus, the association diosgenin/HEL could be used as a model of chemically induced cellular differentiation and anticancer treatment.
  • The goal of this work was to determine the capacity of sedimentation field-flow fractionation (SdFFF) to sort megakaryocytic differentiated cells.
  • As demonstrated by cell size measurement methods, cellular morphology, ploidy, and phenotype, we obtained an enriched, sterile, viable, and functional fraction of megakaryocytic cells.
  • Thus, SdFFF is proposed as a routine method to prepare differentiated cells that will be further used to better understand the megakaryocytic differentiation process.
  • [MeSH-major] Cell Differentiation / drug effects. Cell Separation / methods. Diosgenin / pharmacology. Fractionation, Field Flow / methods. Megakaryocytes / cytology
  • [MeSH-minor] Cell Line, Tumor. Cell Size / drug effects. Humans. Leukemia, Erythroblastic, Acute / pathology. Leukemia, Erythroblastic, Acute / physiopathology. Platelet Membrane Glycoprotein IIb / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16806034.001).
  • [ISSN] 0003-2697
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platelet Membrane Glycoprotein IIb; K49P2K8WLX / Diosgenin
  •  go-up   go-down


5. Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath Y, Matherly LH, Taub JW: The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res; 2004 Jan 15;64(2):728-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of several GATA1 binding sites in the CDAsf promoter and the uniform detection of GATA1 mutations in DS megakaryocytic leukemia suggested the potential role of GATA1 in regulating CDA transcription and the CDAsf promoter acting as an enhancer.
  • Additional identification of the mechanisms of differential expression of genes encoding enzymes involved in ara-C metabolism between DS and non-DS myeloblasts may lead to improvements in AML therapy.
  • [MeSH-minor] Base Sequence. Cell Death / drug effects. Cell Line, Tumor. Cells, Cultured. DNA Primers. Erythroid-Specific DNA-Binding Factors. Exons / genetics. GATA1 Transcription Factor. Humans. Introns / genetics. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14744791.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA92308
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / Erythroid-Specific DNA-Binding Factors; 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 0 / Transcription Factors; 04079A1RDZ / Cytarabine; EC 3.5.4.1 / Cytosine Deaminase
  •  go-up   go-down


6. Hager ED, Dziambor H, Höhmann D, Winkler P, Strama H: Effects of lithium on thrombopoiesis in patients with low platelet cell counts following chemotherapy or radiotherapy. Biol Trace Elem Res; 2001 Nov;83(2):139-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of lithium on thrombopoiesis in patients with low platelet cell counts following chemotherapy or radiotherapy.
  • Therapy for neoplasma is limited by hematological side effects of tumor-destructive therapy and, in part, makes expensive supportive care necessary to overcome and treat leukopenia and thrombocytopenia and their consequences.
  • Thrombocytopenia is a major clinical problem caused by chemotherapy and radiotherapy.
  • Other cytokines, such as interleukin-1 (IL-1), IL-6, and tumor-necrosis factor-alpha (TNF-alpha), are also stimulated.
  • Apart from granulocyte-macrophage-CSF (GM-CSF), there have as yet been no reports of lithium salts inducing early activating factors for the megakaryocytic lineage, such as IL-3, IL-11, stem cell factor and flt-3 ligand, or maturation factors, such as thrombopoietin (TPO).
  • A statistically significant increase in the mean number of platelets for patients with cell counts below 150,000/microL on the commencement of treatment with lithium carbonate could be observed.
  • Patient tolerability of lithium carbonate therapy is very good.
  • Patients with persistent leukopenia and thrombocytopenia following chemotherapy or radiotherapy can be treated with this trace element very cost-effectively.
  • Unfortunately this treatment has not gained acceptance in clinical oncology in the face of extremely cost-intensive treatment with recombinant GM-CSF, IL-11 or, potentially, thrombopoietin.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Lithium / therapeutic use. Radiotherapy / adverse effects. Thrombocytopenia / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Leukocyte Count. Leukopenia / blood. Male. Middle Aged. Neoplasms / blood. Neoplasms / complications. Neoplasms / therapy. Platelet Count

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. LITHIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11762531.001).
  • [ISSN] 0163-4984
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9FN79X2M3F / Lithium
  •  go-up   go-down


7. Brugger W, Scheding S, Ziegler B, Bühring HJ, Kanz L: Ex vivo manipulation of hematopoietic stem and progenitor cells. Semin Hematol; 2000 Jan;37(1 Suppl 2):42-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These manipulations include the positive selection of CD34+ cells for tumor-cell reduction and/or T-cell depletion, the ex vivo expansion of hematopoietic progenitor and stem cells under appropriate cytokine-stimulated culture conditions, and the ex vivo generation of myeloid or megakaryocytic postprogenitor cells and Immune effector cells.
  • This article summarizes both the preclinical data on the ex vivo expansion of hematopoietic progenitor and stem cells from purified CD34+ cells and the Initial clinical studies with ex vivo-expanded stem and progenitor cells for hematopoietic support after high-dose chemotherapy.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10718158.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Congresses; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD34
  • [Number-of-references] 55
  •  go-up   go-down


8. Rassidakis GZ, Georgakis GV, Oyarzo M, Younes A, Medeiros LJ: Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol; 2004 Aug;17(8):946-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • c-Kit receptor (CD117) is expressed by erythroid, megakaryocytic, and myeloid precursors and mature mast cells and has been reported to be expressed in CD30+ lymphomas such as Hodgkin's disease and anaplastic large-cell lymphoma.
  • Imatinib mesylate, a well-established inhibitor of bcr-abl tyrosine kinase, and currently used for the treatment of patients with chronic myeloid leukemia, also inhibits c-kit receptor kinase activity.
  • In view of the possible use of imatinib as experimental therapy for patients with c-kit-positive tumors, we assessed c-kit expression in CD30+ cell lines and lymphomas.
  • Furthermore, treatment with imatinib did not inhibit proliferation of cell lines in vitro.
  • Our data demonstrate that expression of c-kit receptor is exceedingly rare among CD30+ lymphomas and lymphomatoid papulosis, suggesting that c-kit receptor is unlikely to be an appropriate target for therapeutic options such as imatinib in patients with these tumors.
  • [MeSH-minor] Antigens, CD30 / analysis. Antineoplastic Agents / pharmacology. Benzamides. Cell Division / drug effects. Cell Line, Tumor. Flow Cytometry. Hodgkin Disease / genetics. Hodgkin Disease / metabolism. Hodgkin Disease / pathology. Humans. Imatinib Mesylate. Immunohistochemistry. Piperazines / pharmacology. Pyrimidines / pharmacology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15105813.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


9. Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M, Estrov Z, Mills GB, Andreeff M: Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia; 2004 Feb;18(2):267-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the effects of LY294002 in megakaryocytic leukemia-derived MO7E cells, primary AML and normal bone marrow progenitor cells.
  • In conclusion, the data suggest that the inhibition of the PI3K/AKT signaling pathway restores apoptosis in AML and may be explored as a novel target for molecular therapeutics in AML.
  • [MeSH-minor] Cell Line, Tumor. Chromones / pharmacology. Drug Interactions. Humans. MAP Kinase Signaling System / drug effects. Morpholines / pharmacology. Phosphorylation / drug effects. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-akt. Tretinoin / pharmacology. bcl-Associated Death Protein

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14628071.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / P01 CA55164
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BAD protein, human; 0 / Carrier Proteins; 0 / Chromones; 0 / Morpholines; 0 / Proto-Oncogene Proteins; 0 / bcl-Associated Death Protein; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 5688UTC01R / Tretinoin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


10. Drexler HG, Matsuo Y, MacLeod RA: Malignant hematopoietic cell lines: in vitro models for the study of erythroleukemia. Leuk Res; 2004 Dec;28(12):1243-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is striking that many cell lines though committed to either the erythroid or megakaryocytic lineage tend to co-express features of the other lineage, consistent with the concept of a common erythroid-megakaryocytic progenitor.
  • Several cell lines may be induced to differentiate along the erythroid, megakaryocytic or monocytic pathway by treatment with pharmacological or physiological reagents.
  • [MeSH-major] Cell Line, Tumor. Erythroid Cells / pathology. Leukemia, Erythroblastic, Acute / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15475063.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Editorial; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 67
  •  go-up   go-down


12. Orsolić N, Basić I: Antitumor, hematostimulative and radioprotective action of water-soluble derivative of propolis (WSDP). Biomed Pharmacother; 2005 Dec;59(10):561-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several studies suggest that dietary supplementation with antioxidant can influence the response to chemotherapy as well as the development of adverse side effects caused by treatment with chemotherapeutic agents.
  • Using CBA mouse model, we investigated a clinically potential use of a water-soluble derivative of propolis (WSDP) in the treatment of various cytopenias induced by radiation and/or chemotherapy.
  • Tumor was a transplantable mammary carcinoma (MCa) of CBA mouse.
  • Metastases in the lung were generated by injecting viable tumor cells intravenously (iv).
  • WSDP (50 or 150 mg/kg) exerted a significant antimetastatic effect (P < 0.001) when given either before or after tumor cell inoculation.
  • In combined treatment WSDP and Epirubicin profoundly inhibited metastasis formation; this synergistic effect is maximal when Epirubicin and WSDP were administrated after tumor cell inoculation.
  • Positive outcome of combined treatment with WSDP and Epirubicin was also found regarding the number of red and white blood cells in peripheral blood while in mice treated with Epirubicin alone the significant drop in all hematological parameters was noticed on day 13 after tumor cell inoculation.
  • WSDP given either for 20 or 40 days increased cellularity of hematopoietic tissue and the number of leucocytes in peripheral blood; prolonged treatment with WSDP also elevated myeloid and megakaryocytic types of CFUs.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Hematopoiesis / drug effects. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Mammary Neoplasms, Experimental / drug therapy. Propolis / pharmacology. Radiation-Protective Agents / pharmacology
  • [MeSH-minor] Administration, Oral. Animals. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Blood Cell Count. Cells, Cultured. Disease Models, Animal. Drug Therapy, Combination. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Gamma Rays. Injections, Intraperitoneal. Leukopenia / etiology. Leukopenia / prevention & control. Macrophages, Peritoneal / drug effects. Macrophages, Peritoneal / metabolism. Male. Mice. Mice, Inbred CBA. Neoplasm Transplantation. Solubility. Time Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202559.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Radiation-Protective Agents; 3Z8479ZZ5X / Epirubicin; 9009-62-5 / Propolis
  •  go-up   go-down


13. Mishima Y, Terui Y, Mishima Y, Taniyama A, Kuniyoshi R, Takizawa T, Kimura S, Ozawa K, Hatake K: Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors. Cancer Sci; 2008 Nov;99(11):2200-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We observed the excessive autophagy in chronic myelogenous leukemia (CML) cell line, K562, associated with treatment of 12-O-tetradecanoyl-phorbol-13-acetate (TPA), which can induce K562 cells to differentiate into megakaryocytic lineage.
  • Confocal microscopic analysis demonstrated that autophagic cells did not express a megakaryocyte marker, the CD41 molecule, indicating that the autophagy was independent of megakaryocytic differentiation.
  • Autophagy has not been considered during imatinib treatment; nonetheless, co-treatment with imatinib and chloroquine markedly enhanced imatinib-induced cell death, compared to K562 cells treated only with imatinib.
  • Furthermore, imatinib-resistant cell lines, BaF3/T315I and BaF3/E255K, also underwent cell death by co-treatment with imatinib and chloroquine.
  • The block of autophagy could be a new strategy in the treatment of CML.
  • [MeSH-major] Autophagy / drug effects. Drug Resistance, Neoplasm. Protein Kinase Inhibitors / pharmacology. Protein-Tyrosine Kinases / antagonists & inhibitors
  • [MeSH-minor] Cell Death. Cell Differentiation. Cell Line, Tumor. Humans. K562 Cells. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Tetradecanoylphorbol Acetate / pharmacology. Tetradecanoylphorbol Acetate / therapeutic use

  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18823378.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Protein-Tyrosine Kinases; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


14. Tímár J, Tóvári J, Rásó E, Mészáros L, Bereczky B, Lapis K: Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. Oncology; 2005;69(3):185-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stem cell mimicry of cancer cells has been known for a long time and is considered to be responsible for ectopic gene expressions.
  • The stem cell characteristics of tumor cells are shown to be involved in epithelial-mesenchymal transition and in the phenomenon of vascular mimicry.
  • Certain cancer types acquire a geno-phenotype closely resembling the platelets and express several megakaryocytic genes (adhesion receptors alpha IIb beta 3, thrombin receptor and PECAM/CD 31 and/or platelet-type 12-LOX) able to activate the coagulation cascade or the platelets themselves.
  • Data all support that platelet mimicry of certain cancer types is an important factor in their hematogenous dissemination and provides an attractive therapeutic target.
  • Besides the long-available preclinical data, clinical trials have only recently provided evidence that targeting platelet mimicry of cancers is an efficient way to prevent tumor progression.
  • The systematic discovery of the markers of platelet mimicry in various cancer types and their molecular targeting may provide new supportive therapeutic modalities for the management of the progressing disease.
  • [MeSH-minor] Animals. Blood Coagulation Disorders / drug therapy. Blood Coagulation Disorders / etiology. Gene Expression Regulation, Neoplastic. Genotype. Humans. Megakaryocytes / metabolism. Neoplasm Metastasis / genetics. Phenotype. Platelet Aggregation Inhibitors / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 16138000.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors
  • [Number-of-references] 166
  •  go-up   go-down


15. Vasconcellos MC, Bezerra DP, Fonseca AM, Pereira MR, Lemos TL, Pessoa OD, Pessoa C, Moraes MO, Alves AP, Costa-Lotufo LV: Antitumor activity of biflorin, an o-naphthoquinone isolated from Capraria biflora. Biol Pharm Bull; 2007 Aug;30(8):1416-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pharmacological studies with an aqueous extract obtained from leaves of Capraria biflora showed potent cytotoxic, analgesic, antimicrobial and anti-inflammatory activities.
  • It has been demonstrated that biflorin possesses an in vitro cytotoxic activity against tumor cells.
  • The results showed a decrease in Ki67 staining in tumor cells from treated-animals when compared with non-treated groups, which suggests an inhibition of tumor proliferation rate.
  • It was also demonstrated that biflorin acts as an immunoadjuvant agent, rising the production of ovalbumin-specific antibodies and inducing a discreet increase of the white pulp and nest of megakaryocytic in spleen of treated mice, which can be related to its antitumor properties.
  • [MeSH-minor] Adjuvants, Immunologic / pharmacology. Animals. Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Ehrlich Tumor / drug therapy. Carcinoma, Ehrlich Tumor / pathology. Female. Fluorouracil / therapeutic use. Immunohistochemistry. Indicators and Reagents. Ki-67 Antigen / metabolism. Mice. Neoplasm Transplantation. Ovalbumin / immunology. Sarcoma 180 / drug therapy. Sarcoma 180 / pathology

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17666796.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Indicators and Reagents; 0 / Ki-67 Antigen; 0 / Naphthoquinones; 0 / biflorin; 9006-59-1 / Ovalbumin; U3P01618RT / Fluorouracil
  •  go-up   go-down


16. Liu HC, Chen SH, Wang LY, Yeh TC, Chai IJ, Liang DC: In vitro cell growth stimulated by recombinant human cytokines can help to diagnose transient leukemia in neonates. J Formos Med Assoc; 2007 May;106(5):365-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytospin smears of liquid suspension cultures all showed good myeloid or megakaryocytic maturation consistent with TL rather than AML.
  • Among four patients followed long-term, one developed myelodysplastic syndrome at 21 months.
  • This child was given tailored chemotherapy and had a disease-free survival>20 months.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561471.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-3; 0 / Recombinant Proteins; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 9014-42-0 / Thrombopoietin
  •  go-up   go-down


17. Maurer AM, Zhou B, Han ZC: Roles of platelet factor 4 in hematopoiesis and angiogenesis. Growth Factors; 2006 Dec;24(4):242-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Structure-function studies have shown that the DLQ determinant in position 54-56 is necessary for megakaryocytic inhibition whereas mutations of these residues into ELR sequence and more importantly, into DLR sequence, induce a stronger inhibitory activity of peptide p47-70 on angiogenesis.
  • In vivo, PF4 and its related peptides can protect hematopoiesis from chemotherapy by enhancing cell viability and suppress tumor growth through anti-angiogenic pathway.
  • Several PF4 fragments and modified molecules exhibit antiangiogenesis properties and may become an alternative for further therapeutic angiogenesis.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Hematopoiesis. Neovascularization, Pathologic / metabolism. Neovascularization, Physiologic. Platelet Factor 4 / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17381065.001).
  • [ISSN] 0897-7194
  • [Journal-full-title] Growth factors (Chur, Switzerland)
  • [ISO-abbreviation] Growth Factors
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Glycosaminoglycans; 0 / Peptides; 37270-94-3 / Platelet Factor 4
  • [Number-of-references] 95
  •  go-up   go-down


18. Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, Stout ML, Buck SA, Massey G, Becton DL, Weinstein HJ, Ravindranath Y, Matherly LH, Taub JW: Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood; 2006 Feb 15;107(4):1570-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
  • Children with Down syndrome (DS) with acute megakaryocytic leukemia (AMkL) have very high survival rates compared with non-DS AMkL patients.
  • Transcripts for the bone marrow stromal-cell antigen 2 (BST2) gene, encoding a transmembrane glycoprotein potentially involved in interactions between leukemia cells and bone marrow stromal cells, were 7.3-fold higher (validated by real-time polymerase chain reaction) in the non-DS compared with the DS group.

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 May;14(5):786-91 [10803507.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1355-60 [15920490.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Mar-Apr;23(3):175-8 [11305722.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3727-32 [11389009.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1713-24 [12200686.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1551-7 [12393509.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4298-300 [12560215.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4301-4 [12586620.001]
  • [Cites] Blood. 2003 Aug 1;102(3):981-6 [12649131.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3415-22 [12885836.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):728-35 [14744791.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3242-3 [15070711.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Br J Haematol. 2004 Jun;125(6):729-42 [15180862.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1617-23 [15343346.001]
  • [Cites] Haematol Blood Transfus. 1989;32:172-7 [2696678.001]
  • [Cites] Blood. 1992 Nov 1;80(9):2210-4 [1384797.001]
  • [Cites] Leuk Res. 1994 Mar;18(3):163-71 [8139285.001]
  • [Cites] Genomics. 1995 Apr 10;26(3):527-34 [7607676.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1428-34 [8618581.001]
  • [Cites] Blood. 1998 Jan 15;91(2):608-15 [9427716.001]
  • [Cites] Biochem Biophys Res Commun. 1999 May 19;258(3):583-91 [10329429.001]
  • [Cites] Leukemia. 1999 Jun;13(6):935-43 [10360383.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1393-400 [10438727.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3679-87 [15226186.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):33-9 [15390307.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):151-68 [15657362.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):226-31 [15687366.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):797-804 [15755283.001]
  • [Cites] Exp Hematol. 2001 Apr;29(4):448-57 [11301185.001]
  • (PMID = 16249385.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES06639; United States / NCI NIH HHS / CA / R01 CA92308
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 04079A1RDZ / Cytarabine; EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ PMC1895418
  •  go-up   go-down


19. Wolber EM, Haase B, Jelkmann W: Thrombopoietin production in human hepatic cell cultures (HepG2) is resistant to IFN-alpha, IFN-beta, and IFN-gamma treatment. J Interferon Cytokine Res; 2002 Dec;22(12):1185-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombopoietin production in human hepatic cell cultures (HepG2) is resistant to IFN-alpha, IFN-beta, and IFN-gamma treatment.
  • Thrombocytopenia is an important complication of interferon (IFN) therapy for chronic viral hepatitis.
  • Neither was the rate of secretion of immunoreactive TPO reduced on IFN treatment.
  • These findings support the concept that IFNs primarily mediate effects on megakaryocytic cells and platelets rather than on TPO-producing hepatocytes.
  • [MeSH-major] Gene Expression Regulation, Neoplastic / drug effects. Interferon-alpha / pharmacology. Interferon-beta / pharmacology. Interferon-gamma / pharmacology. Thrombopoietin / genetics
  • [MeSH-minor] Carcinoma, Hepatocellular. Dose-Response Relationship, Drug. Humans. Kinetics. Liver Neoplasms. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic / drug effects. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12581491.001).
  • [ISSN] 1079-9907
  • [Journal-full-title] Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • [ISO-abbreviation] J. Interferon Cytokine Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / RNA, Messenger; 77238-31-4 / Interferon-beta; 82115-62-6 / Interferon-gamma; 9014-42-0 / Thrombopoietin
  •  go-up   go-down


20. Scheding S, Bergmannn M, Rathke G, Vogel W, Brugger W, Kanz L: Additional transplantation of ex vivo generated megakaryocytic cells after high-dose chemotherapy. Haematologica; 2004 May;89(5):630-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional transplantation of ex vivo generated megakaryocytic cells after high-dose chemotherapy.
  • The additional transplantation of ex vivo generated hematopoietic (post)-progenitor cells represents a possible approach to ameliorate high-dose chemotherapy induced cytopenia.
  • We investigated the feasibility of the large-scale expansion and transplantation of autologous megakaryocytic cells in four patients with advanced solid tumors.
  • [MeSH-minor] Antigens, CD34 / blood. Dose-Response Relationship, Drug. Hematopoietic Stem Cell Mobilization. Hematopoietic Stem Cell Transplantation. Pilot Projects. Transplantation, Autologous. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15136238.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement